Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 3Sarcoma, Clear Cell 2Sarcoma 2Neurofibrosarcoma 2Nerve Sheath Neoplasms 2Liposarcoma 2Histiocytoma, Angiomatoid Fibrous 2Granuloma, Plasma Cell 2Fibrosarcoma 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Vascular Neoplasms 1Solitary Fibrous Tumors 1Solid Neoplasm 1Smooth Muscle Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Perivascular Epithelioid Cell Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neuroendocrine Tumors 1Neoplasms, Adipose Tissue 1Neoplasm Metastasis 1Myoepithelioma 1Liposarcoma, Myxoid 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangioendothelioma, Epithelioid 1Granular Cell Tumor 1

Interventions

pazopanib 1Geriatric Assessment 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Neoplasm × pazopanib × 90 days × Clear all
NCT01552356 2026-04-13

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
54 enrolled

Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡